1Wikler MA,Cockerill FR, Craig WA, et al.Performance standards for antimicrobial susceptibility testing;sixteenth information supplement[S].CLSI,2006:37-45.
6Chang S, Sievert D M, Hageman J C, et al. Infection with Vancomycin resistant Staphylococcus aureus containing the vanA resistance gene [J]. N Engl J Med, 2003, 348 (14): 1342-1347.
7Firsov A A, Vostrov S N, Lubenko I Y, et al. In vitro pharmacodynamic evalution of the mutant selection window hypothesis using for fluoroquinotones against Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2003,47:1604-1613.
8Zhou J, Dong Y, Zhao X, et al. Selection of antibiotic resistant bacterial mutants: Allelic diversity among fluoroquinolone resistant mutations[J]. Infect Dis, 2000, 182 (2): 517-525.
9Drlica K. The mutant selection concentration and antimicrobial resistance[J]. JAntimicrob Chemother, 2003, 52: 11-17.
10Ho P L, Tse W S, Tsang K W T, et al. Risk factors for acquisition of levofloxacin resistant Streptococcus pneumoniae: A case control study[J]. Clin lnfect Dis, 2005, 32(5): 701-707.
6Haluk V,Fatma B,Murat K,et al.High prevalence o f OXA-51-type class D -lactamases among cefta zidim eresista nt clinical isolates of A cinetobacterspp: co-existence with OXA-58 in multiplecent res[J].J Antimicrob Chemother,2006,58(3):537.
7Akram M,Shahid M,Khan AU.Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC hospital aligarh, India [J].Ann Clin Microbiol Antimicrob,2007,23 (3):9-12.
8Wagenlehner FM, Weidner W,Naber KG.Antibiotics in urology: new essentials[J].Urol Clin North Am,2008,35(1):69-73.
10Carvalho AP, Albano RM, deOliveira DN, et al. Characteriza- tion of an epidemic car bapenem resistant Pseudomonas aerugi- nos aproducing SPM21 metallo betalactamase in a hospital lo- eatedin Riode Janeiro, Brazil[J]. Microb Drug Resist,2006,12 (2) :103-108.
